Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2006-06-20
2006-06-20
Kishore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
Reexamination Certificate
active
07063860
ABSTRACT:
The present invention relates to compositions and methods for the administration of lipid-based vehicles to treat various disorders, including bladder inflammation, infection, dysfunction, and cancer. In various aspects, the compositions and methods of the invention are useful for prolonged delivery of drugs, e.g., antibiotics, pain treatments, and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system, and other organs or body systems. In particular, the present invention relates to liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin, and toxins, such asbotulinumtoxin, for the treatment of bladder conditions, including pain, inflammation, incontinence, and voiding dysfunction. Further related are methods of using these vehicles alone or in conjunction with antibodies, e.g., uroplakin antibodies, to improve duration of liposome attachment, and provide a long-term intravesical drug delivery platform. The present invention specifically relates to antibody-coated liposomes that are useful for targeting specific receptors for drug, peptide, polypeptide, or nucleic acid delivery. In one particular aspect, the present invention relates to liposomes coated with antibodies against nerve growth factor (NGF) receptor and containing NGF antisense nucleic acids, which are used as a treatment for neurogenic bladder dysfunction.
REFERENCES:
patent: 4708861 (1987-11-01), Popescu et al.
patent: 4932936 (1990-06-01), Dykstra et al.
patent: 5298019 (1994-03-01), Borodic
patent: 5698549 (1997-12-01), Steers et al.
patent: 5763399 (1998-06-01), Lee
patent: 5837694 (1998-11-01), Barrett
patent: 6239267 (2001-05-01), Duckworth et al.
patent: 6271211 (2001-08-01), Christ et al.
patent: 0036277 (1981-09-01), None
de Paiva, A., Dolly, J.O., 1990, “Light chain of botulinum neurotoxin is active in mammalian motor nerve terminals when delivered via liposomes”, FEBS Lett, 277(1-2):171-4.
Paavola, A., Kilpelainen, I., Yliruusi, J., Rosenberg, P., 2000, “Controlled release injectable liposomal gel of ibuprofen for eipdural analgesia”, Int. J. Pharm., 199(1):85-93.
Boogaerts, J.G., Lafont, N.D., Declercq, A.G., Luo, H.C., Gravet, E.T., Bianchi, J.A., Legros, F.J., 1994, “Epidural administration of liposome-associated bupivacaine for the management of post-surgical pain: a first study”, J. Clin. Anesth., 6(4):315-20.
Lafont, N.D., Legros, F.J., Boogaerts, J.G., 1996, “Use of liposome-associated bupivacaine in a cancer pain syndrome”, Anaesthesia, 51(6):578-9.
Sharma, A., Shamra U.S., Straubinger, R.M., 1996, “Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia”, Cancer Lett, 107(2):265-72.
Fagerli J, Fraser MO, deGroat WC, Chancellor MB, Flood HD, Smith D, Jordan ML. “Intravesical capsaicin for the treatment of interstitial cystitis: a pilot study.” Can J Urol. Apr. 1999;6(2):737-744.
Lazzeri M, Beneforti P, Benaim G, Maggi CA, Lecci A, Turini D. “Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study.” J Urol. Sep. 1996;156(3):947-52.
Meddings, JB, Hogaboam, CM, Tran K., Reynolds, JD, Wallace, JL, 1991, “Capsaicin effects on non-neuronal plasma membranes”, Biochim Biophys Acta, 1070(1):43-50.
Tsuchiya H., 2001, “Biphasic membrane effects of capsaicin, an active component in Capsicum species”, J. Ethnopharmacol, 75(2-3):295-9.
Johnson, JW, Nayar R., Killion, JJ, von Eschenbach, AC, Fidler, IJ, 1989, “Binding of liposomes to human bladder tumor epithelial cell lines: implications for an intravesical drug delivery system for the treatment of bladder cancer”, Sel Cancer Ther, 5(4):147-55.
Kiyokawa H., Igawa, Y., Muraishi, O., Katsuyama, Y., Iizuka, K., Nishizawa, O., 1999, “Distribution of doxorubicin in the bladder wall and regional lymph nodes after bladder submucosal injection of liposomal doxorubicin in the dog”, J. Urol., 161(2):665-7.
Barton, KN, Buhr, MM, Ballantyne, JS, 1999, “Effects of urea and trimethylamine N-oxide on fluidity of liposomes and membranes of an elasmobranch”, Am J. Physiol., 276(2 Pt 2):R397-406.
Zhou, F, Kraehenbuhl, JP, Neutra, MR, 1995, “Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes”, Vaccine, 13(7):637-44.
Egerdie RB, Reid, G., Trachtenberg, J., 1989, “The effect of liposome encapsulated antineoplastic agents on transitional cell carcinoma in tissue culture”, J. Urol, 142(2 Pt l):390-8.
Wright, EM, Bindslev,N., 1976, “Thermodynamic analysis of nonelectrolyte permeation across the toad urinary bladder”, J. Membr Biol., 29(3):289-312.
Filion, Mario C. et al., Anti-inflammatory activity of cationic lipids, British J. Pharmacology, 122:551-559, 1997.
Chancellor Michael B.
Chuang Yao-Chi
de Groat William C.
Fraser Matthew O.
Huang Leaf
Kishore Gollamudi S.
The Webb Law Firm
University of Pittsburgh
LandOfFree
Application of lipid vehicles and use for drug delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Application of lipid vehicles and use for drug delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Application of lipid vehicles and use for drug delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3638428